Telmisartan (Micardis)
telmisartan
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Hypertension | Adults | Monotherapy or combination | FDA Approved |
| Cardiovascular risk reduction | Adults at high CV risk, unable to take ACE inhibitors | Add-on to standard therapy | FDA Approved |
Telmisartan is a long-acting ARB with the unique distinction of being the only angiotensin II receptor blocker carrying an FDA-approved indication for cardiovascular risk reduction in patients who cannot tolerate ACE inhibitors. The ONTARGET programme demonstrated non-inferiority of telmisartan 80 mg to ramipril 10 mg for major cardiovascular endpoints in high-risk patients, with better tolerability (less cough and angioedema). For hypertension, telmisartan provides sustained 24-hour blood pressure control due to its ~24-hour half-life, with most antihypertensive effect seen within 2 weeks and maximal effect by 4 weeks.
Diabetic nephropathy / proteinuria reduction: ARBs as a class reduce proteinuria in diabetic kidney disease; telmisartan has been studied in several trials for this purpose. Evidence quality: Moderate.
Metabolic syndrome (PPAR-γ modulation): Telmisartan is a partial agonist of PPAR-γ and has shown improvements in insulin sensitivity, glucose metabolism, and lipid parameters in clinical studies, though it is not FDA-approved for this purpose. Evidence quality: Low–Moderate.
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hypertension — initial monotherapy | 40 mg once daily | 20–80 mg once daily | 80 mg/day | BP response is dose-related over 20–80 mg; doses >80 mg do not appear to provide further reduction. Maximal effect at 4 weeks. Administer with or without food |
| Hypertension — volume- or salt-depleted patient | 20 mg once daily | 20–80 mg once daily | 80 mg/day | Correct volume/salt depletion before initiation or start under close medical supervision to avoid symptomatic hypotension FDA PI recommends correction before therapy or close supervision; 20 mg is the lowest available tablet strength |
| Cardiovascular risk reduction — high-risk patients unable to take ACE inhibitors | 80 mg once daily | 80 mg once daily | 80 mg/day | Based on ONTARGET/TRANSCEND. It is not known whether doses lower than 80 mg are effective for CV risk reduction (FDA PI). Monitor BP and adjust other antihypertensives as needed |
| Hepatic impairment (any indication) | 20–40 mg once daily | Titrate slowly | 40 mg/day (EMA recommendation) | Bioavailability approaches 100% in hepatic impairment. Initiate under close supervision with biliary obstructive disorders. Not studied in severe hepatic impairment Primarily eliminated via bile; use caution |
With a terminal half-life of approximately 24 hours, telmisartan provides the most sustained AT1 receptor blockade among currently available ARBs. This translates to effective 24-hour blood pressure control, including the critical early morning surge period, which is associated with increased cardiovascular events. In ONTARGET, the 80 mg dose showed non-inferiority to ramipril 10 mg for cardiovascular outcomes, making it the preferred dose for patients requiring cardiovascular protection.
Safety and effectiveness of telmisartan in paediatric patients have not been established. Telmisartan pharmacokinetics have not been investigated in patients younger than 18 years (FDA PI).
Pharmacology
Mechanism of Action
Telmisartan is a non-peptide benzimidazole derivative that selectively blocks the angiotensin II type 1 (AT1) receptor with high affinity. By blocking AT1-mediated vasoconstriction, aldosterone secretion, and sympathetic activation, telmisartan lowers blood pressure and reduces cardiac afterload. Its binding to the AT1 receptor is functionally insurmountable, meaning the inhibitory effect persists even as angiotensin II concentrations rise. Uniquely among ARBs, telmisartan functions as a partial agonist of peroxisome proliferator-activated receptor gamma (PPAR-γ), activating this nuclear receptor at approximately 25–30% of full agonist activity. This PPAR-γ modulation may confer metabolic benefits including improved insulin sensitivity and favourable effects on lipid metabolism, without the fluid retention risks associated with full PPAR-γ agonists such as thiazolidinediones. Telmisartan does not inhibit ACE and therefore does not promote bradykinin accumulation, explaining the placebo-equivalent cough rate of 1.6%.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapidly absorbed; Tmax 0.5–1 h; bioavailability dose-dependent (42% at 40 mg, 58% at 160 mg); food reduces AUC by 6–20% | Can be taken with or without food (reduction is not clinically significant per FDA PI). Non-linear PK means higher doses yield greater-than-proportional exposure increases |
| Distribution | Vd ~500 L; protein binding >99.5% (albumin and α1-acid glycoprotein); does not penetrate RBCs reversibly | Largest Vd of any ARB, indicating extensive tissue distribution. Plasma levels 2–3× higher in women; no dose adjustment needed |
| Metabolism | Glucuronidation to inactive telmisartan glucuronide; NOT metabolised by CYP450 system; minor CYP2C19 inhibition | Very low CYP interaction potential. Not a prodrug (unlike candesartan or olmesartan). >97% excreted unchanged |
| Elimination | t½ ~24 h; total plasma clearance >800 mL/min; >97% excreted unchanged via bile/faeces; <1% in urine; not removed by hemofiltration | Once-daily dosing with true 24-hour coverage. Predominantly biliary elimination means hepatic impairment profoundly affects exposure (bioavailability approaches 100%); renal impairment has minimal effect |
Side Effects
Telmisartan has been evaluated for safety in more than 3,700 patients. In placebo-controlled trials (telmisartan n=1,455; placebo n=380), the overall adverse event incidence was similar to placebo. Adverse experiences were generally mild and transient (FDA PI). In the ONTARGET trial (n=25,620), telmisartan demonstrated less cough and angioedema compared with ramipril.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Upper respiratory tract infection | 7% (vs 6% placebo) | Most frequent adverse event in hypertension trials; generally mild and self-limiting |
| Back pain | 3% (vs 1% placebo) | Mechanism unclear; not dose-dependent; may warrant evaluation if persistent |
| Sinusitis | 3% (vs 2% placebo) | Mild; no specific management required |
| Diarrhea | 3% (vs 2% placebo) | Usually self-limiting; ensure adequate hydration |
| Pharyngitis | 1% (vs 0% placebo) | Mild; rarely requires discontinuation |
Events occurring at ≥1% but no higher than placebo (not attributed to drug): headache, dizziness, fatigue, coughing, myalgia, dyspepsia, nausea, peripheral oedema, abdominal pain. Cough incidence was identical to placebo (1.6%).
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Intermittent claudication | 7% (vs 6% placebo) | Serious AE ≥1% above placebo in ONTARGET/TRANSCEND; may reflect underlying vascular disease rather than drug effect |
| Skin ulcer | 3% (vs 2% placebo) | Serious AE ≥1% above placebo; assess for peripheral vascular aetiology |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Fetal toxicity | Class effect | 2nd/3rd trimester exposure | Discontinue immediately upon detection of pregnancy |
| Angioedema | Very rare (1 in 3,781 in clinical trials; fatal cases post-marketing) | Any time during treatment | Discontinue permanently; emergency airway management; do not rechallenge |
| Rhabdomyolysis | Rare (post-marketing) | Variable | Discontinue; IV hydration; monitor CK and renal function |
| Acute renal failure | Rare | Days to weeks, especially in volume-depleted or bilateral renal artery stenosis | Hold drug; volume resuscitation; reassess RAS blockade |
| Hyperkalaemia (significant) | Uncommon (higher with dual RAS blockade) | Weeks, especially with K-sparing agents or renal impairment | Reduce or stop dose; correct potassium; review concomitant medications |
| Symptomatic hypotension | Uncommon; orthostatic hypotension after first dose 0.04% | First dose or initiation | Supine positioning; IV fluids; consider dose reduction |
The incidence of cough with telmisartan in six placebo-controlled trials was identical to placebo (1.6%). In ONTARGET, telmisartan produced significantly less cough and angioedema than ramipril 10 mg, making it a preferred alternative for patients who develop ACE inhibitor–related cough.
Drug Interactions
Telmisartan is not metabolised by the CYP450 system, substantially reducing the risk of pharmacokinetic interactions common with other drugs. It does show minor inhibition of CYP2C19. Key interactions are pharmacodynamic, involving dual RAS blockade, potassium homeostasis, lithium clearance, and digoxin levels.
Monitoring
-
Blood Pressure
Each visit; 2–4 weeks after initiation
Routine Maximal antihypertensive effect within 4 weeks. For CV risk reduction indication, monitor and adjust other antihypertensives as needed (FDA PI). First-dose symptomatic orthostasis rate is very low (0.04%). -
Serum Potassium
Baseline; periodically thereafter
Routine Especially important with concomitant potassium-sparing agents, ACE inhibitors, or renal impairment. In ONTARGET, the combination with ramipril increased hyperkalaemia risk. -
Renal Function
Baseline; periodically
Routine Creatinine rise ≥0.5 mg/dL occurred in only 0.4% vs 0.3% placebo in HTN trials. Monitor more closely in patients with bilateral renal artery stenosis, severe HF, or volume depletion. -
Haemoglobin
As clinically indicated
Trigger-based A decrease >2 g/dL occurred in 0.8% of telmisartan patients vs 0.3% placebo. No patients discontinued for anaemia. Check if symptomatic. -
Hepatic Function
If symptoms develop
Trigger-based No patients discontinued for hepatic function in trials. However, telmisartan is eliminated primarily via bile; patients with biliary obstruction or hepatic insufficiency need careful monitoring. Occasional liver chemistry elevations occurred but were more frequent with placebo. -
Digoxin Levels
When co-prescribed
Trigger-based Median increases in digoxin peak plasma concentration (49%) and trough concentration (20%) reported per FDA PI. Monitor when initiating, adjusting, or discontinuing telmisartan. -
Pregnancy Status
Before initiation and as applicable
Routine Discontinue immediately when pregnancy is detected (FDA boxed warning). Counsel women of childbearing potential regarding reliable contraception.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan or any component
- Pregnancy (2nd and 3rd trimesters — FDA boxed warning; avoid throughout pregnancy when possible)
- Co-administration with aliskiren in patients with diabetes mellitus
Relative Contraindications (Specialist Input Recommended)
- Bilateral renal artery stenosis or stenosis of a solitary kidney — risk of acute renal failure
- Severe hepatic impairment — telmisartan is predominantly eliminated via bile; bioavailability approaches 100% in hepatic impairment
- Biliary obstructive disorders — reduced clearance expected; initiate under close supervision
- Concomitant ACE inhibitor use — ONTARGET demonstrated no benefit and increased adverse events with combination (FDA PI specifically states not recommended)
Use with Caution
- Volume or salt depletion — correct before initiating or start under close supervision
- Patients with severe congestive heart failure — oliguria, progressive azotaemia, and rarely acute renal failure reported with RAS blockade
- Patients of Black race — blood pressure response is noticeably less than in Caucasian patients (low-renin population); consider combination therapy
- Elderly patients — PK does not differ; however, greater sensitivity of some individuals cannot be ruled out
Drugs that act directly on the renin–angiotensin system can cause injury and death to the developing fetus when used during the second and third trimesters. Reported complications include oligohydramnios, skull hypoplasia, lung hypoplasia, anuria, hypotension, renal failure, limb contractures, and death. When pregnancy is detected, telmisartan should be discontinued as soon as possible.
Patient Counselling
Purpose of Therapy
Telmisartan blocks the effects of a hormone called angiotensin II that raises blood pressure and puts strain on the heart and blood vessels. By lowering blood pressure, telmisartan reduces the long-term risk of heart attack and stroke. In some patients at high cardiovascular risk, it also provides direct protective effects on the heart and blood vessels.
How to Take
Take telmisartan once daily at the same time each day, with or without food. Tablets come in individual blister packs — do not remove a tablet until you are ready to take it. Do not stop taking telmisartan without consulting your prescriber, even if you feel well, as high blood pressure often has no symptoms.
Sources
- Boehringer Ingelheim. Micardis (telmisartan) tablets — FDA-approved prescribing information. Revised December 2014. DailyMed Primary regulatory source for all indications, dosing, adverse event rates, PK data, and contraindications cited in this monograph.
- Boehringer Ingelheim. Micardis (telmisartan) tablets — FDA Label 2012. FDA Supplementary FDA label version with complete adverse event tables from hypertension placebo-controlled trials.
- Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events (ONTARGET). N Engl J Med. 2008;358(15):1547–1559. DOI Landmark trial (n=25,620) demonstrating telmisartan 80 mg is non-inferior to ramipril 10 mg for cardiovascular outcomes; basis for the CV risk reduction indication.
- Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to ACE inhibitors (TRANSCEND). Lancet. 2008;372(9644):1174–1183. DOI Companion trial to ONTARGET in ACEi-intolerant patients; showed trend toward CV benefit, with the HOPE-equivalent secondary endpoint reaching significance.
- Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (ONTARGET). Lancet. 2008;372(9638):547–553. DOI Renal outcomes from ONTARGET; combination therapy worsened major renal outcomes compared to monotherapy.
- Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2025;86(18):1567–1678. PubMed Most current US hypertension guideline; includes ARBs as first-line agents for blood pressure control.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263–e421. DOI US heart failure guideline; positions ARBs in the treatment algorithm for patients intolerant to ACEi/ARNI.
- Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension. 2004;43(5):993–1002. DOI Foundational study characterising telmisartan’s unique partial PPAR-γ agonist activity, distinguishing it from other ARBs.
- Imenshahidi M, Roohbakhsh A, Hosseinzadeh H. Effects of telmisartan on metabolic syndrome components: a comprehensive review. Biomed Pharmacother. 2024;171:116169. DOI Comprehensive review of telmisartan’s metabolic effects through PPAR modulation, including insulin sensitivity, lipid metabolism, and anti-inflammatory properties.
- Stangier J, Schmid J, Türck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol. 2000;40(12 Pt 1):1312–1322. DOI Definitive radiolabelled PK study establishing bioavailability (~43%), biliary excretion (>98% faecal), and glucuronidation as the sole metabolic pathway.
- Stangier J, Su CA, Hendriks MG, et al. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol. 2000;40(12 Pt 1):1355–1364. DOI Established that hepatic impairment increases Cmax 6.4-fold and AUC 2.7-fold; absolute bioavailability approaches 100% in these patients.
- McClellan KJ, Markham A. Telmisartan. Drugs. 1998;56(6):1039–1044. DOI Early drug profile establishing telmisartan’s pharmacological characteristics including the longest half-life among ARBs.